Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Microsoft

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing #ai and behavioral science to personalize each user’s health journey, and how this approach can help improve #diversity...

Impetus Digital

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

Up to 80% of squamous cell carcinomas develop from actinic keratosis lesions

- PMLiVE

NICE announces launch of digital and AI advice service for healthcare sector

Four UK healthcare organisations collaborated on the AI and Digital Regulations Service

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC

Train your brain for success

In this episode of Impetus Digital‘s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Max Newlon, President of Brain Co. They discuss everything from...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links